Stock CTMX CYTOMX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Real-time Estimate Cboe BZX
Other stock markets
 09:34:02 2024-06-10 am EDT 		5-day change 1st Jan Change
1.635 USD -0.30% Intraday chart for CytomX Therapeutics, Inc. -3.53% +5.81%
May. 28 Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25 MT
May. 09 BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25
MT
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
AQ
CytomX Therapeutics Announces New Employment Inducement Grants
AQ
CytomX Therapeutics : Definitive Additional Materials
PU
CytomX Therapeutics : Annual Meeting Rules of Conduct
PU
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating
MT
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904
AQ
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3
MT
CytomX Therapeutics : First Quarter Earnings Update - May 8, 2024
PU
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M
MT
Transcript : CytomX Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
CytomX Therapeutics: Q1 Earnings Snapshot
AQ
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
AQ
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
AQ
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)
CI
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8
MT
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTMX Stock
  4. News CytomX Therapeutics, Inc.